Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs

Autor(es)

Miguel, Rodrigo dos A. ; Hirata, Amanda S. ; Jimenez, Paula C. ; Lopes, Luciana B. ; Costa-Lotufo, Leticia V.

• Tipo de documento: Artigo Científico
• Fonte: PHARMACEUTICS; v. 14, n. 8, p. 28-pg., 2022-08-01.

Resumo

Nature is the largest pharmacy in the world. Doxorubicin (DOX) and paclitaxel (PTX) are two examples of natural-product-derived drugs employed as first-line treatment of various cancer types due to their broad mechanisms of action. These drugs are marketed as conventional and nanotechnology-based formulations, which is quite curious since the research and development (R&D) course of nanoformulations are even more expensive and prone to failure than the conventional ones. Nonetheless, nanosystems are cost-effective and represent both novel and safer dosage forms with fewer side effects due to modification of pharmacokinetic properties and tissue targeting. In addition, nanotechnology-based drugs can contribute to dose modulation, reversion of multidrug resistance, and protection from degradation and early clearance; can influence the mechanism of action; and can enable drug administration by alternative routes and co-encapsulation of multiple active agents for combined chemotherapy. In this review, we discuss the contribution of nanotechnology as an enabling technology taking the clinical use of DOX and PTX as examples. We also present other nanoformulations approved for clinical practice containing different anticancer natural-product-derived drugs. (AU)

• Processo FAPESP: 20/09270-4 - Desenvolvimento de nanopartículas de albumina para a veiculação de seriniquinona
• Beneficiário: Rodrigo dos Anjos Miguel
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 18/13877-1 - Nanocarreadores para a quimioprevenção e tratamento localizado de tumores de mama
• Beneficiário: Luciana Biagini Lopes
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores - Fase 2
• Processo FAPESP: 20/06613-8 - Caracterização do mecanismo de ação da seriniquinona em células de Melanoma resistentes ao vemurafenibe
• Beneficiário: Amanda Soares Hirata
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 15/17177-6 - Abordagem integrada na prospecção sustentável de produtos naturais marinhos: da diversidade a substâncias anticâncer
• Beneficiário: Leticia Veras Costa Lotufo
• Modalidade de apoio: Auxílio à Pesquisa - Programa BIOTA - Temático